Genetic variants of transthyretin amyloidosis with cardiomyopathy associated with low sensitivity to bone scintigraphy: a systematic review
In brief
Thirteen inherited transthyretin variants were linked to low-uptake bone scans
A review of 19 studies covering 108 patients identified 13 inherited transthyretin variants associated with absent or low bone-scan uptake; three variants were implicated most consistently. In 11 of the 13 variants, advanced heart muscle disease was documented despite negative scans, and scans missed disease in about 5% to 10% of Val142Ile carriers. A negative scan cannot rule out cardiac amyloidosis in genetically at-risk patients.
- Journal
- Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (Q1)
- Published
- 19 November 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Federico Giannino, Roberto Licordari, Alessia Piccolo, Lorenzo Bianchi, Luigi Colarusso, Stefania Marazia, et al.
- PMID
- 43055171
- DOI
- 10.1080/13506129.2026.2756364
Why clinicians should know about it
- Picked for Genetics (clinical) (top studies of the week, 22 November 2026): Systematic review guides surveillance and diagnosis in hereditary TTR disease
Abstract
BACKGROUND: Transthyretin cardiac amyloidosis (ATTR-CA) is characterized by amyloid deposition and frequently leads to a progressive cardiomyopathy with poor prognosis. Bone scintigraphy with 99mTc-labeled tracers is the cornerstone of noninvasive diagnosis, yet several hereditary TTR variants are associated with false-negative or low-grade tracer uptake. OBJECTIVES: To identify all TTR variants associated with false-negative bone scintigraphy in hereditary ATTR-CA and discuss clinical implications. METHODS: Medline, Scopus, and Cochrane were searched from inception to July 2025 per PRISMA guidelines. Eligible studies included observational studies, case series, and case reports of patients with confirmed ATTR-CA undergoing TTR genetic testing and 99mTc scintigraphy. RESULTS: Nineteen studies (108 patients) met inclusion criteria. Thirteen pathogenic TTR variants were associated with low or absent uptake (Perugini grade 0-1); p.Val50Met, p.Phe84Leu, and p.Ser97Tyr were most consistently implicated, while p.Val142Ile showed false-negative results in ∼5-10% of carriers. In 11 of 13 variants, advanced structural cardiomyopathy was confirmed despite negative scintigraphy. CONCLUSIONS: Bone scintigraphy has important limitations in specific hereditary TTR variants. A negative scan does not exclude cardiac involvement in genetically at-risk patients. Multimodal strategies including CMR and histological assessment are essential for timely diagnosis.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.